AUTHORS: Craig Whittington, PhD.; Todd Feinman, M.D.; Sandra Zelman Lewis, PhD., Greg Lieberman, B.S.; Michael del Aguila, PhD.
CONFERENCE: Clinical Onmuno-Oncology Smposium (ASCO-SITC)
DATE: February 28- March 2, 2019.
Background and Objectives
In 2018, ASCO published a guideline on how clinicians should manage immunerelated adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICPis).